nanger Lane Ealing London W₅ 3QR

T: +44 (0)20 8799 8200 F: +44 (0)20 8799 8201

E: enquiries@antisoma.com W: www.antisoma.com



Office of International Corporate Finance Division of Corporate Finance Mail Stop 3628 United States Securities and Exchange Commission 100 F Street, NE

Washington, D.C. 20549 U.S.A.

Tuesday 12 December 2006

Ladies and Gentlemen:

Antisoma plc

Pursuant to Rule 12g3-2(b) under the United States Securities Exchange Act of 1934, as amended (the "Exchange Act"), we hereby furnish you with certain documentation that we have made public or filed with the UK Listing Authority, the London Stock Exchange or the Registrar of Companies for England and Wales at Companies House or distributed to our shareholders and which is listed in Annex 1 to this letter.

These documents supplement the information previously provided with respect to Antisoma plc's request for exemption under Rule 12g3-2(b), which was established on November 21, 2005.

This information is being furnished with the understanding that such information and documents will not be deemed "filed" with the SEC or otherwise subject to the liabilities of Section 18 of the Exchange Act, and that neither this letter nor the furnishing of such documents and information shall constitute an admission for any purpose that Antisoma plc is subject to the Exchange Act.

Please do not hesitate to contact the undersigned at +44 20 8799 8200 in the United Kingdom if you have any questions.

Thank you for your attention.

Yours faithfully For and on behalf Antisoma plc

THOMSON FINANCIAL

Name: Simone Tinney

Title: Communication Assistant

Registered Office: West Africa House, Hanger Lane, Ealing, London W5 3QR, UK Registered in England No. 3248123

Holding(s) in Antisoma

London, UK, 12 December 2006 - Antisoma plc (LSE: ASM, US OTC: ATSMY) received notification yesterday from Orbimed Advisors, LLC, ("Orbimed") that, following a purchase of 375,000 ordinary shares on December 7 2006, Orbimed and its founder and Managing Member, Samuel D. Isaly, each had an interest in 11,365,000 ordinary shares, representing approximately 3.1% of Antisoma's issued ordinary shares.

- END -

Enquiries: Daniel Elger, Director of Communications Antisoma plc +44 (0) 20 8799 8200